论文部分内容阅读
[目的]观察芪胶升白胶囊联合重组人粒细胞集落刺激因子治疗宫颈癌化疗后骨髓抑制疗效。[方法]使用随机平行对照方法,将80例住院患者按随机数字表方法简单随机分为两组。对照组40例给予重组人粒细胞集落刺激因子,2~5μg/kg,1次/d,皮下或静注,化疗给药结束后用药。治疗组40例化疗开始前2d,给予芪胶升白胶囊饭后口服,2g/次,3次/d;重组人粒细胞集落刺激因子治疗同对照组。连续治疗21d为1疗程。观测临床症状、白细胞计数、不良反应。治疗1疗程(21d),判定疗效。[结果]治疗组显效21例,有效16例,无效3例,总有效率92.50%;对照组显效12例,有效18例,无效10例,总有效率75.00%;治疗组疗效优于对照组(P<0.01)。白细胞计数治疗组改善优于对照组。[结论]芪胶升白胶囊联合重组人粒细胞集落刺激因子治疗宫颈癌化疗后骨髓抑制,疗效满意,无严重不良反应,值得推广。
[Objective] To observe the curative effect of bone marrow suppression after chemotherapy of cervical cancer treated with QLSL combined with recombinant human granulocyte-colony stimulating factor. [Methods] Using randomized parallel control method, 80 inpatients were randomly divided into two groups according to random number table method. Control group of 40 patients given recombinant human granulocyte colony stimulating factor, 2 ~ 5μg / kg, 1 / d, subcutaneously or intravenously, chemotherapy after the end of medication. The treatment group 40 patients 2 days before the start of chemotherapy, giving glibenclamide capsule orally after oral administration, 2g / time, 3 times / d; recombinant human granulocyte colony stimulating factor treatment with the control group. Continuous treatment of 21d for a course of treatment. Observation of clinical symptoms, white blood cell count, adverse reactions. Treatment of a course of treatment (21d), determine the efficacy. [Results] In the treatment group, 21 cases were markedly effective, 16 cases were effective, 3 cases were ineffective, and the total effective rate was 92.50%. In the control group, 12 cases were markedly effective, 18 cases were effective, 10 cases were ineffective and the total effective rate was 75.00% (P <0.01). WBC count was better in the treatment group than in the control group. [Conclusion] QGSG combined with recombinant human granulocyte colony-stimulating factor in the treatment of myelosuppression after cervical cancer chemotherapy has satisfactory curative effect and no serious adverse reactions, which is worth popularizing.